Opko Health, Inc. · NASDAQ:OPK
Opko Health — Investor Presentation (January 2021)
25 slides from Opko Health's investor presentation, Jan 13, 2021
Slide 1: OPKO Health January 2021
January 2021 NASDAQ: OPK
Slide 2: Forward-looking statements
January 2021 | 2 This presentation contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,
Slide 3: Pharmaceutical and Diagnostic platforms in growing healthcare markets
January 2021 | 3 Pharmaceutical and Diagnostic platforms in growing healthcare markets Diagnostics Pharmaceuticals Third largest full service lab in US, 300- person commercial team drives industry- leading esoteric testing Best-in-breed genetic test offerings and most comprehensive menu in the indus
Slide 4: Somatrogon Summary
January 2021 | 4 Somatrogon© Summary • Somatrogon© (hGH-CTP), a once-weekly growth hormone replacement therapy, was proven non-inferior to daily Genotropin® (somatropin) with respect to height velocity after 12 months • Height velocity at 12 months of treatment was higher in the somatrogon© group (1
Slide 5: Somatrogon CTP Technology
Somatrogon© (hGH-CTP) consists of the natural peptide sequence of native growth hormone and three copies of the 28 amino acids of the C-Terminus Peptide of human chorionic gonadotropin hormone. This NCE, compared to current GH replacement therapies, is designed to reduce the injection frequency from
Slide 6: Somatrogon Path To Approval
January 2021 | 6 Somatrogon© Path To Approval •BLA submission accepted for review by US FDA as well as Canada and Australia •PDUFA Date for October 2021 •NDA submission in Japan anticipated 1H 2021 MAA submission in Europe anticipated 1H 2021
Slide 7: Diversified Assets: Marketed Pharmaceuticals
January 2021 | 7 Diversified Assets Marketed Pharmaceuticals Pipeline Diagnostics
Slide 8: Rayaldee: first and only extended-release prohormone of vitamin D3
• Once daily oral formulation of the prohormone 25D3* addresses significant unmet need • Only product approved by FDA to treat secondary hyperparathyroidism (SHPT) in patients with stage 3-4 CKD and vitamin D insufficiency • Reduces plasma iPTH and increases serum 25D, with safety profile similar to
Slide 9: Rayaldee for Patients with Stage 5 CKD and Vitamin D Insufficiency
• Commenced September 2018 • Approximately 44 patients treated for 26 weeks • Interim data released in March 2020 • Topline data expected in 1Q 2021 • Costs shared with Vifor Fresenius and Japan Tobacco January 2021 | 9 Rayaldee for Patients with Stage 5 CKD and Vitamin D Insuffiency Phase 2 open-la
Slide 10: Ongoing Phase Study with Rayaldee in COVID-19 Patients
January 2021 | 10 ONGOING PHASE 2 STUDY WITH RAYALDEE IN COVID-19 PATIENTS Outcome: - Prevention of more serious symptoms - Faster recovery Day -3 Day -3 Days 1-27 Days 28-42 Screening Randomization Treatment Follow-up Title: A Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety
Slide 11: Diversified Assets: Broad Development Pipeline
January 2021 | 11 Diversified Assets Broad Development Pipeline Marketed Pharmaceuticals DiagnosticsPipeline
Slide 12: Rare Disease Pipeline In Development
INDICATION PRODUCT MARKET SIZE PRECLINICAL PHASE 1 PHASE 2 PHASE 3 Growth Hormone Deficiency (GHD) hGH-CTP (Adults) $4.0B hGH-CTP (Children) Other Pediatric Growth Hormone Disorders hGH-CTP Hemophilia Factor VIIa-CTP (IV) $0.6B Factor VIIa-CTP (SC) IGF-1 Deficiency IGF-1-CTP $0.2B Bowel Disorders GL
Slide 13: Diversified Assets: Diagnostics
January 2021 | 13 Diversified Assets One of the Nation’s Largest Reference Laboratories Marketed Pharmaceuticals DiagnosticsPipeline
Slide 14: OPKO's BioReference 2020 Overview
January 2021 | 14 OPKO’s BioReference 2020 Overview Patients Served Annually Requisitions Daily 2019 40,000+ 2020 115,000 2019 4,000 2020 8,100 Staff Clinical Staff 2019 11M 2020 19M 2019 120 2020 300
Slide 15: Areas of Focus with Customized Solutions
January 2021 | 15 Areas of Focus with Customized Solutions COVID-19 Digital Health Core Business Strategic Venture Services
Slide 16: COVID-19 Response
16 COVID-19 Response Physicians & Hospitals January 2021 | Education GovernmentSports Employers RetailTravel & Leisure Large scale screening and point-of-care testing
Slide 17: NFL Enhancement
January 2021 | 17 NFL Enhancement
Slide 18: COVID-19 Diagnostic Offerings
18*numbers as of January. 2021 COVID-19 Diagnostic Offerings 10,000,000+ Molecular Tests Performed* 100,000+ Molecular Tests Per Day Capacity* 60,000+ Point-of-Care Tests Performed* January 2021 |
Slide 19: The Future of COVID-19 Testing for 2021
19 The Future of COVID-19 Testing for 2021 • Many factors continue to drive demand for COVID-19 testing at BioReference Laboratories. o Retail access remains imperative for the general public. o Physicians will continue to test their patients. o Employers are working through their strategies for emp
Slide 20: Core Business Areas
January 2021 | 20 Core Business Areas Clinical Women’s Health Oncology Urology Genetics
Slide 21: Digital Health
January 2021 | 21 Digital Health
Slide 22: Scarlet Health in-home digital solution
• BioReference is the only national laboratory to offer an in-home, fully integrated digital solution of mobile phlebotomy and laboratory services • About Scarlet: • Efficient, convenient and safe to use for physicians and patients. • Inspired by digital platforms consumers use daily to provide ease
Slide 23: Strategic Venture Services
January 2021 | 23 Strategic Venture Services A mid-Atlantic integrated health care provider with more than 2,600 physicians Provides laboratory management and reference testing. Services include: • Design and buildout of the core laboratory • Day-to-day management of the operations • Implementation
Slide 24: GeneDx – Global Leader in Rare Genetic Disorders
January 2021 | 24 GeneDx – Global Leader in Rare Genetic Disorders Leader in rapid exome and genome testing Largest provider of exome sequencing, performing nearly 5,000 exomes per month. Leader in pediatric rare disease with most Children's hospitals across the country as a client. One of the large
Slide 25: Select Financial Information September 30, 2020
January 2021 | 25 Select Financial Information September 30, 2020 • Cash, cash equivalents & marketable securities: $36.3 million • Un-utilized $100m unsecured credit facility and $64.7m available under ABL with J.P. Morgan Chase resulting in more than $200m of capital available • Net investments: $